Focused On-demand Library for Cytoplasmic dynein 2 intermediate chain 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96EX3

UPID:

DC2I2_HUMAN

Alternative names:

Dynein 2 intermediate chain 2; WD repeat-containing protein 34

Alternative UPACC:

Q96EX3; Q5VXV4; Q9BV46

Background:

Cytoplasmic dynein 2 intermediate chain 2, also known as Dynein 2 intermediate chain 2 or WD repeat-containing protein 34, plays a pivotal role in the cytoplasmic dynein 2 complex. This complex is essential for the movement of cargos along microtubules within cilia and flagella, facilitating retrograde ciliary protein trafficking and ciliogenesis. It also acts as a negative regulator of the Toll-like and IL-1R receptor signaling pathways, inhibiting the MAP3K7-induced NF-kappa-B activation pathway.

Therapeutic significance:

Given its crucial role in ciliogenesis and signaling pathways, Cytoplasmic dynein 2 intermediate chain 2 is implicated in Short-rib thoracic dysplasia 11 with or without polydactyly, a condition affecting skeletal and organ development. Understanding the role of this protein could open doors to potential therapeutic strategies for treating this and related ciliopathies.